Kenneth Lynard Email & Phone Number

Amsterdam, Nh, Nl

Hoofddorp, North Holland, Nl

To be updated…

Prague 10, Cz

High quality, fast growing pan-European Generics, OTC and Speciality Pharmaceutical Company (2023: €1.5bn revenue).Member of the Executive Committee and Advisory Board. Engaged in all major strategic and transformational matters. Leading all activities across Finance, Treasury, Tax, Digital/IT, Indirect Procurement and Risk & Assurance, and heavily involved with M&A (incl. Integrations) and Business Development & In-licensing (>80 deals/year), R&D (yearly spend 5% of revenues), Sustainability/ESG (incl. CSRD implementation) and numerous transformational programs/initiatives, such as (examples) Sales & Operations Planning (S&OP), Inventory Optimisation (-30 days coverage/DIO, -€50m), YoY COGS reduction (yearly 2%, net of inflation), Portfolio Segmentation and Pruning, and new functional Target Operating Models (Supply Chain, Quality and Finance). Closely connected with other Advisory Board members and Investor Representatives.Extensive list of achievements available upon request.

The Hague, Nl

Largest Pan-European Medical Services Operator for Advanced Diagnostic Imaging and Cancer Care(2018: €500m revenue).Member of the Management- and Supervisory Boards and ‘co-pilot’ to the Group CEO. Directly led and mentored highly diverse teams of 300 performing professionals across Finance, Treasury, Tax, M&A, Integrations, Digital/IT, Procurement, Facilities Management and Risk & Assurance. Key stakeholder in all major strategic, organisational and operational matters driving alignment amongst Executive Leadership, Board and Investors. Ensured ‘focus with speed’ execution.Completed extensive Finance benchmarking, leading to ‘blueprint’ for significant improvement of all core processes, systems, upgrade of competencies while lowering costs (% of revenue) from 3 to 1.5.Successfully trained and educated the broader leadership team in critical financial planning, analysis and investment processes, providing specific market and operational data to support decision making, and improving forecast accuracy.Deployed comprehensive cost optimisation program across 250+ sites (baseline €250m, target -5%/year), through improved measurement (KPIs), target setting to force prioritisation, and increase in volume of bundled procurements.Driving force in M&A origination, applying market intelligence to identify and assess attractiveness of targets and defining opportunities to accelerate growth and realise synergies. More than 10 deals completed (€50m+ revenues).Steering cross-functional efforts to accelerate integration of 3 significant acquisitions (Spain, Portugal, Romania).Core member of the executive team working on concrete options to transform the Company though large-scale global M&A, and radically improve the digitalisation across all major operational aspects.Led full Group re-financing (€550m), achieving improved terms and extended maturity.

Foster City, Ca, Us

Global biopharma provider of solutions for HIV, Liver and Oncology therapeutics (2015: $32bn revenue)Managed and mentored a diverse group of over 180 top performing professionals. Deeply involved in driving strategic planning, budgeting, operational execution and performance management. Active member of Executive Commercial and Global CFO leadership teams. Effectively led FP&A, Accounting, Revenue Recognition, Cash Management, FX Hedging and Tax Optimisation and Compliance across multiple entities worldwide.Selected to play central role in launching new cutting-edge products into existing and new international markets; built and led finance teams, partnered with the business to generate multi-billion ($) in new revenue yearly.Greatly improved fundamental financial planning & analysis processes to continually enhance accuracy and provide long- term support for executive decisions, via detailed analytical insights and follow-up by product and market.Integrated member of the extended controllership team driving external reporting requirements (SEC), Sarbanes-Oxley (SOX) compliance and preparation for Earnings Calls.Core member of the senior team, who raised over $10B+ in new capital and maintained investor communication.Reinstated the Global Pricing Committee, including members from multiple functions, focusing on instituting flexible processes to quickly respond to and align with changing market conditions when setting product prices.Chosen for cross-functional Steering Group to implement company-wide strategy for expanding manufacturing and commercial activities into China; handled all finance-related aspects.

Gilead Sciences (global biopharma provider), United Kingdom: Vice President & CFO EMA (2012-2013).Medtronic (world leader, medical technology), Switzerland: CFO Europe, MEA & Asia (2007-2012).Coloplast (world leader, medical devices), Germany: CFO Central Europe & Head of GFS (2003-2007).Superfos Packaging (PE-owned manufacturing), Germany: CFO, Consumer Division (1999-2003).Arthur Andersen (BIG5 audit), Denmark: Manager Responsibility, Large Clients (1991-1999).Danske Bank (banking), Denmark: Advisor, Private and Corporate Clients (1988-1991).

Executive Mba (Emba), Business Administration And Management, General

Master Science, Business Economics & Auditing (Cand.Merc.Aud)